Bank of America Securities analyst Geoff Meacham maintained a Sell rating on CureVac (CVAC – Research Report) yesterday and set a price target of $10.00. The company’s shares closed yesterday at $9.90.
According to TipRanks, Meacham is a 4-star analyst with an average return of 5.8% and a 54.99% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Biogen, and Bristol Myers.
CureVac has an analyst consensus of Moderate Buy, with a price target consensus of $19.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $17.21 and a one-year low of $5.63. Currently, CureVac has an average volume of 522.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company’s product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
Read More on CVAC:
